Janux Therapeutics (JANX) Reiterated at Buy by UBS After JANX007 Ph1 update
Tweet Send to a Friend
UBS analyst David Dai reiterated a Buy rating and $57.00 price target on Janux Therapeutics (NASDAQ: JANX).The analyst commented, "JANX ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
